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Talk Outline 
• Review Treatment of Patients with Sepsis
• Review the Benefits and Limitations of Single Center vs Multicenter Clinical Trials
• Discuss the evidence supporting use of  Vitamin C, Thiamine, and Steroids in Sepsis
• To Describe the Design of the VICTAS  study ( Vitamin C, Thiamine and Steroids in Sepsis ) 
Patient JM
• 66 year old with CML- extra lymphatic 
involvement S/P ABMT 60 days prior to 
admission
– Admitted with GVHD with GI symptoms
– Noted to have tachypnea to 30’s B/P 90/55 pulse 108 
T 38.5 wbc 1.2 lactate 4
– Blood cultures oxidase positive gram negative rods
– Started on ceftazidime
– Transferred to ICU when required non-rebreather
Infection
Organ failure
Sepsis is a Medical Emergency
Concept  Highlighted by Manny Rivers
Proper Orientation is Important
Sepsis Care Must Center Around the Patient
• Treatment 
• Similar conditions
Sepsis is a Medical Emergency
Sepsis is…
• Life-threatening organ dysfunction caused by a 
dysregulated host response to infection1
• Common: 0.9-3 million cases/yr2, 3
• Life-threatening: 15-30% mortality2
• Time-sensitive: 8% mortality increase for 
every hour delay in initiation of antibiotics4
• A major public health concern: most 
expensive reason for US hospitalization5,6
1. Singer et al. JAMA 2016 4. Kumar et al. CCM 2006
2. Gaieski et al. CCM 2013  5. Elixhauser et al.  AHRQ Report 2011
3. Martin et al. NEJM 2003 6. Torio and Andrews. AHRQ Report 2013  
Sepsis is a Syndrome
• Disease
• Known Biomarker
• Diagnostic Test that enables 
identification
• Syndrome
• Constellation of signs and 
syndromes that lead to 
diagnosis
Sepsis Diagnosis- Not Always Simple
Partnering with Patients and Advocacy Groups
What is in the Sepsis Treatment Toolbox ?
• Early Recognition of Sepsis
• Early Antibiotics and Fluids
• Performance Improvement Projects
Timing of Antibiotics in Sepsis Induced Hypotension
• 2731 Patients with septic shock
• 44% Admissions From ED
– Lung, Intra-abdominal and  Urine most 
common sites of infection
• Mortality Rate 21% if Effective Antibiotics 
given within 1 hour
• Mortality Rate 58% if Effective Antibiotics 
given within 6 hours
Kumar et al Crit Care Med 2006;34:1589-1596
Following Sepsis Guidelines Helps Patients
New Engl J Med 2017;23;2335-44
Timeliness of Antibiotics associated with mortality
Timeliness of Fluids Not 
associated with mortality
Not every patient gets treatment consistent with guidelines
Ferrer, R. et al. JAMA 2008;299:2294-2303.
Performance of Outcome Measurements: Did the Campaign Work?
Small Increase in Process Measures 
Decreased Mortality Rate
• Increasing Compliance with Sepsis Bundle is 
Associated with Decreasing Patient Mortality
• Compliance with early bundles was associated 
with decreased need for later intervention
• Lung protective Mechanical Ventilation, 
inotropes, and steroids were interventions 
independently associated with mortality
Am J Resp Crit Care Med 2013:188:77-82
Following Sepsis Guidelines Helps Patients
Not all sepsis patients get desired treatment
Time to Completion of 3 hour bundle associated 
with in hospital mortality
New Engl J Med 2017;23;2335-44
7.5 year Evaluation of a PI project on Sepsis ( SSC)  
Critical Care Medicine 2015:43:3-12.
Resuscitation Compliance includes 
among other things 30 cc/kg /IVF 
Serum Tumor Necrosis Factor Levels After Endotoxin 
Challenge
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TNF given to animals 
challenged with endotoxin
– reverse hemodynamic 
embarrassment
– improve mortality
Tracey et. al Science 1987;330:662-4.
Sevransky and Natanson Sepsis 1999:3:11-19
Clinical Sepsis Trials of Monoclonal 
Antibodies Directed Against TNF
Treatment Directed at Modulating 
Inflammation: Not Effective
Clinical Sepsis Trials That Did Not Show Beneficial Treatment Effect

Triple Therapy for Sepsis
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Biologic Rationale Vitamin C in Sepsis
• Antioxidant and enzyme co-
factor 
– Activates Nrf2 
– Restores cellular antioxidants
– Catecholamines
• Anti-inflammatory
– ↓ NF-ĸB
• Necessary for tight junctions 
and microcirculatory flow
Thiamine
• Essential for aerobic metabolism:
– Pyruvate dehydrogenase
– Alpha ketoglutarate dehydrogenase
Thiamine and Vitamin C
Vitamin C
Oxalic Acid
Glyoxalic acid
Carbon Dioxide
Thiamine
Phase I Study of Vitamin C in Sepsis
• Patients- 26 Patients with severe sepsis ( 1.0) at VCU randomized 1:1:1
• Intervention Vitamin C 50 mg/kg/day in divided doses  every 6 hours for 96 hours 
• Or
• Vitamin C 200 mg/kg/day in divided doses every 6 hours for 96 hours
• ComparatorPlacebo
• Outcome measure- Sequential Organ Failure Assessment ( SOFA scores) and 
Vitamin C Levels
Journal of Translational Medicine 2014, 12:32
Phase I Study of Vitamin C in Sepsis
Journal of Translational Medicine 2014, 12:32
Thiamine in Sepsis
• Patients- Adult patients with septic shock and elevated (> 3 
mmol/L) lactate between 2010 and 2014 at 2 hospitals
• Intervention —Thiamine 200 mg twice daily for 7 days or until 
hospital discharge.
• Comparator- Placebo treated patients 
• Outcome Lactate level 24 hours after first study dose
Thiamine in Sepsis
Triple Therapy for Sepsis
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Rationale for Marik study
• Preliminary data
• Patients with sepsis have low serum levels of 
Vitamin C
• Patients with sepsis have low serum levels of 
thiamine
• Small studies have shown feasible to give supplemental 
Vitamin C and thiamine without obvious harm
• Potential synergistic effect of steroids and Vitamin C
Before-After Study 
• Patients – 47 consecutive patients admitted to the ICU at Sentara Norfolk General Hospital with a 
primary diagnosis of severe sepsis or septic shock and a procalcitonin ≥ 2ng/ml
• Intervention: intravenous vitamin C (1.5 gm q 6 hourly for 4 days or until ICU discharge), 
hydrocortisone (50 mg q 6 hourly for 7 days or until ICU discharge followed by a taper over 3 days), 
intravenous thiamine (200 mg q 12 hourly for 4 days or until ICU discharge).
• Comparator Patients with severe sepsis and septic shock with procalcitonin ≥ 2ng/ml treated during 
previous year without vitamin C or thiamine, but who could receive hydrocortisone per physicians 
orders
• Outcome Measure Hospital Survival
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Additional analysis
• Propensity score:
– Probability (0-1) of 
receiving treatment 
based on covariates
• Logistic regression 
for OR mortality
1. Propensity score 
2. Propensity score + 
age
Covariates
Age
Weight
Gender
APACHE IV Score
Mechanical Ventilation
Vasopressors
WBC
Lactate
Procalcitonin
Serum Creatinine
Before-After Study 
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Study Limitations
Single Center before and after study
Complex intervention
Steroids used in comparator arm
Little information about contemporaneous therapies ( antibiotics, fluids etc)
Confirmation bias
Large effect size 
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Highly Polarizing Results
• A significant number of professionals 
immediately began prescribing this as a 
cure for sepsis
• A significant number of professionals 
criticized the study very vociferously
• Much of this discussion has been high-
level intellectual discourse
• Some of it has not been
Ann Int Med 1964:759-776
38% ARR
27% ARR
Single Vs Multicenter Trials 
Phase II Single Center Trials
• Test potential novel  therapies
• Show potential risks and benefits
• Easier to do/Cheaper
• May change practice at one site or with 
some physicians
• May have large treatment effects
Phase III Multicenter Trials
• Test Potential new therapies
• Show potential risks and benefits
• Harder to do/More expensive
• The gold standard for changing clinical 
practice
• Usually with smaller treatment effects
Why We Need a Clinical Trial 
Why We Need a Clinical Trial
Viewpoint 1 Viewpoint 2
• “It might help- that’s why I used it”
• I’m on service right now and thought I’d relay an event 
that occurred simultaneous to the foundation 
presentation.  We have a patient who was found 
down and seems to have acute on chronic liver 
disease with septic shock, AKI, DIC and ARDS.  She was 
given thiamine because of the alcoholism and steroids 
because of refractory shock (vasopressin and 50+ mcg 
of norepinephrine).  Because she was doing poorly 
despite a couple of days of maximal therapy the 
resident (all credit due) decided to add Vitamin C to 
the steroids and thiamine already being given.  Within 
24 hours her vasopressin was turned off and her 
norepinephrine was 2-5mcg.  In full disclosure she 
also got NAC and albumin because of liver disease and 
possible HRS, but still!
• To my knowledge, we have had zero patients 
treated at Vanderbilt.  But Jon, you should 
emphasize this does not reflect any lack of 
enthusiasm for conducting a proper study, it 
reflects Vanderbilt’s long-standing 
conservatism regarding “new” or “exciting” 
therapies, i.e., we believe it is proper to wait 
until there is sufficient high quality data to 
begin routinely using these treatments on 
everyday patients.
• Gordon Bernard MD
What Kind of Evidence Should Change Practice ?
1- Single Physician and Single Patient
2- Single Institution
3- Most Patients
4- Treatment Guidelines
• Clinical Experience, Literature
• Clinician Agreement +  Data Showing that 
Practice Change Works in that Institution
• > 1 RCT in a similar patient population
• >1 RCT in similar patient population + 
evaluation of quality of RCT + cost and 
downside of intervention
CHEST (2017), doi: 10.1016/j.chest.2016.11.036
Phase III Multicenter Trials Change Practice
An  Analogy For Multicenter vs. Single Center Trials
New York Knicks vs Cleveland Cavaliers Oct 30th 2017 NY 114 –Cleveland 95
• A multicenter trial is more likely to be reproduced than is a single center trial,  
just as a 7 or 82 game series is more likely to give the same result if repeated.
Trial Design- What Patient Population to Pick
Critically Ill Patients: 
Mortality Endpoint
• More likely to immediately 
change practice 
• Simpler Enrollment Criteria
• Fewer patients
• More sites required
• May take longer to complete
Very Sick but Not Yet Critical:
Rates & Speed  of Improvement Endpoint
• Preventing progression to Critically Ill-
-May be appealing to Patients
• Applies to More Patients
• More complicated enrollment criteria
• Could be less compelling for immediate 
practice change
Consider nested study including both populations
Design Considerations
• Patients- which patient population are your studying
• Intervention- What are You Giving
• Comparator- What Treatment does the non-intervention arm get
• Outcome – What is the primary outcome measure
Victas PICO Questions
• Patients- Up to 2000 Adult patients with confirmed or suspected infection and evidence of 
respiratory or cardiovascular organ dysfunction (e.g. adult sepsis)
• Intervention Intravenous vitamin C (1.5 grams every 6 hours), thiamine (100 mg every 6
hours), and hydrocortisone (50 mg every 6 hours), will be administered in divided doses 
each day for 4 days or until ICU discharge.
• Comparator Placebo ( unless clinical team desires to give steroids)
• Outcome- Vasopressor and Ventilator Free Days
- 30 day mortality
Inclusion Criteria
• Patients > 18 with confirmed or suspected infection and evidence of 
respiratory or cardiovascular organ dysfunction 
• Confirmed or  suspected infection :ordering of blood cultures and 
administration of at least one antimicrobial agent
• Respiratory Dysfunction
– Positive pressure ventilation ( invasive or non invasive)
– High Flow Nasal Cannula ( >=45 L >=45%%)
• Cardiovascular Dysfunction
– Vasopressors
Exclusion Criteria
Designed to limit exclusions 
and make the study as pragmatic as possible
• Patients that are too ill from other causes in which the treatment is 
unlikely to fix the other problems (e.g., end stage cancer)
• Patients who refuse to participate
• Patients who are allergic to any of the treatments
• Patients with medical conditions that would make treatment higher risk 
(kidney stones, problems metabolizing calcium)
• Patients who are participating in another study
Sample Size
500 Patients- Simulation Data
If the Mortality 
Difference is 10% 
between groups, 
500 patients 
would have 80% 
power to show it.
Estimates of Patients Needed 
According To Differences in Mortality Between Treatment Groups
Treatment 
Effect
Patients Needed to Show 
Treatment Effect
32% 72
20% 250
10% 500
5% 2000
← Marik Manuscript 
Treatment Effect
Estimates Dependent Upon Mortality Rates in Control Group 
Pr=Probability
PFVD- vasopressor 
and ventilator free 
days ( i.e alive and 
off vasopressors and 
ventilators)
Analytic Plan
• Final analysis will be done after all enrolled subjects are followed to 
Primary Endpoint
• For Vasopressor and Ventilator Free Days will use a Wilcoxon Rank 
Sum Test, using 1 sided alpha of 0.022 (to adjust to control Type I 
error rate at 0.025)
• In final analysis, patients who died are treated as though they had 
zero Ventilator and Vasopressor Free Days
• Managed with DCC, with assistance from Berry Consultants
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VICTAS Team
Jun Oct Feb Jun Oct Feb Jun Oct
2017 2018 2019
Kick-off Meeting
1/10/2018
6 Active Sites
3/31/2018
14 Active Sites
5/31/2018
1st Patient Enrolled
7/1/2018
22 Active Sites
7/31/2018
Close-out Meeting
12/1/2019
3 Active Sites
2/28/2018
10 Active Sites
4/30/2018
18 Active Sites
6/30/2018
25 Active Sites
8/31/2018
500th Patient Enrolled
8/31/2019
Submit Final Report 
and Publication 
12/31/2019
Jun 1 Dec 31
Phase A: 
Planning
Jan 1 Oct 31
Phase B: Initiation, IRB 
Approval Start-up, 25 Sites 
Jan 1 Feb 28Obtain IND
Jan 1 Jul 1Obtain IRB Approval Initial Sites
Jan 1 Jul 1Prepare Sites for Launch
Jul 1 Aug 31Enroll Patients (approx. 38/month)
Sep 1 Oct 31Complete Follow-up Data Collection 
Nov 1 Dec 31Phase C: Completion of Study
Nov 1 Dec 31Closeout: Data Analysis and Publications
500 Patient Milestones
250th Patient Enrolled
1/26/2019
• Thank you
• Jsevran@emory.edu
